NGS

Cornell researchers plan to test cell-free DNA in a prospective study for diagnosing infection and antimicrobial resistance in kidney transplant patients.

The European Commission recently awarded Cergentis a €1.2 million grant to support the development of its TLA technology for use in FFPE samples.

The German drugmaker plans to advance the NSCLC treatment in parallel with tissue-based and liquid biopsy companion assays that can identify best responders.

The Belgian cancer center plans to evaluate Natera's ctDNA assay for evaluating response and detecting minimal residual disease in breast cancer patients. 

Under a definitive merger agreement, Roche will acquire outstanding shares of Foundation's common stock for $137 per share.

The researchers designed a transcriptome sequencing assay that identifies clinically relevant gene fusions in 541 genes.

With its purchase of decision support technology maker Interactive Biosoftware, Sophia looks to extend its AI platform deeper into NGS interpretation.

The startup has developed a transposon-based sample prep technology that is able to prepare both small and large RNA molecules in one RNA-seq library.

Eric Green, NHGRI director

Fifteen years after the Human Genome Project was declared completed, genomic medicine is beginning to be implemented, sooner than Green and others had expected.

The UK-based firm recently launched its Nadia system, which is compatible with the Drop-seq protocol, and plans to develop additional applications. 

Pages

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.